Abstract

The key questions to be addressed are as follows: (1) Project 1 - what is the role of the natural immune response to HTLV-III in individuals infected with the virus? (2) Project 2 - which are the epitopes on the virus envelope glycoproteins that can be exploited for vaccine production? (3) Project 3 - what is the effect of HTLV-III and its components on cellular immune function? (4) Project 4 - what is the significance of macrophage dysfunction in AIDS and is this mediated by HTLV-III or its gene products? (5) Project 5 - what are the consequences of HTLV-III infection in hemophiliacs and how does this differ from other risk groups and (6) Project 6 - can one develop effective anti-viral agents for interventive approaches in already infected individuals? The approaches to be used to answer these questions will employ specialized biological assay systems, native and recombinant viral gene products, synthetic peptides, monoclonal antibodies, anti-viral compound, and mutant virus strains. In addition to pre-clinical studies in vitro or in animal models, actual clinical trials with promising vaccines and anti-viral agents will be engaged.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA043447-05
Application #
3094032
Study Section
Special Emphasis Panel (SRC)
Project Start
1986-07-01
Project End
1991-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
5
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Palker, T J; Muir, A J; Spragion, D E et al. (1996) The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology 224:415-26
Haynes, B F; Pantaleo, G; Fauci, A S (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-8
Liao, H X; Lee, D M; Levesque, M C et al. (1995) N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J Immunol 155:3938-45
Klinman, D M; Haynes, B F; Conover, J (1995) Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides. AIDS Res Hum Retroviruses 11:97-105
Liao, H X; Haynes, B F (1995) Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am 21:715-40
Hart, M K; Palker, T J; Haynes, B F (1995) Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Pharm Biotechnol 6:821-45
Ferrari, G; King, K; Rathbun, K et al. (1995) IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol 101:239-48
Haynes, B F; Moody, M A; Heinley, C S et al. (1995) HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. AIDS Res Hum Retroviruses 11:211-21
Toso, J F; Chen, C H; Mohr, J R et al. (1995) Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 172:964-73
Ferrari, G; Place, C A; Ahearne, P M et al. (1994) Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. J Acquir Immune Defic Syndr 7:325-31

Showing the most recent 10 out of 49 publications